What’s Next for Cytosorbents Corp (CTSO) After Today’s Significant Increase?

September 17, 2017 - By Migdalia James

Investors sentiment decreased to 1.25 in 2016 Q4. Its down 0.53, from 1.78 in 2016Q3. It fall, as 4 investors sold Cytosorbents Corp shares while 8 reduced holdings. 7 funds opened positions while 8 raised stakes. 1.20 million shares or 2.14% less from 1.23 million shares in 2016Q3 were reported.
Morgan Stanley stated it has 0% in Cytosorbents Corp (NASDAQ:CTSO). Fortaleza Asset Management Inc reported 24,875 shares. Vanguard Group Inc has 0% invested in Cytosorbents Corp (NASDAQ:CTSO). Geode Cap Limited Liability Company holds 126,277 shares or 0% of its portfolio. Glenmede Tru Na invested in 0% or 19,008 shares. The California-based California Public Employees Retirement System has invested 0% in Cytosorbents Corp (NASDAQ:CTSO). Northern Tru invested in 24,574 shares or 0% of the stock. Millennium Lc holds 0% of its portfolio in Cytosorbents Corp (NASDAQ:CTSO) for 13,000 shares. Wells Fargo & Mn holds 1,500 shares. Royal National Bank & Trust Of Canada invested in 0% or 2,900 shares. Manufacturers Life Insur The invested in 0% or 2,164 shares. The New York-based Tower Rech Ltd Liability Corporation (Trc) has invested 0% in Cytosorbents Corp (NASDAQ:CTSO). Blackrock Fund Advsr reported 64,489 shares stake. Creative Planning accumulated 0% or 5,500 shares. Natl Bank Of Mellon Corp owns 25,643 shares.

Since May 15, 2017, it had 7 insider purchases, and 0 insider sales for $80,608 activity. 1,500 Cytosorbents Corp (NASDAQ:CTSO) shares with value of $6,180 were bought by BATOR MICHAEL G.. The insider Capponi Vincent bought $10,000. The insider Mortensen Eric R. bought 2,500 shares worth $10,100. The insider BLOCH KATHLEEN P. bought $4,341. Another trade for 2,500 shares valued at $9,987 was bought by Jones Edward Raymond.

The stock of Cytosorbents Corp (NASDAQ:CTSO) is a huge mover today! The stock increased 3.77% or $0.2 on September 15, reaching $5.5. About 170,282 shares traded or 15.08% up from the average. Cytosorbents Corp (NASDAQ:CTSO) has declined 4.26% since September 17, 2016 and is downtrending. It has underperformed by 20.96% the S&P500.
The move comes after 6 months positive chart setup for the $154.74 million company. It was reported on Sep, 17 by Barchart.com. We have $5.67 PT which if reached, will make NASDAQ:CTSO worth $4.64M more.

Analysts expect Cytosorbents Corp (NASDAQ:CTSO) to report $-0.09 EPS on November, 6.They anticipate $0.02 EPS change or 18.18 % from last quarter’s $-0.11 EPS. After having $-0.04 EPS previously, Cytosorbents Corp’s analysts see 125.00 % EPS growth.

Cytosorbents Corp (NASDAQ:CTSO) Ratings Coverage

Among 6 analysts covering CytoSorbents (NASDAQ:CTSO), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CytoSorbents had 10 analyst reports since October 29, 2015 according to SRatingsIntel. As per Tuesday, August 8, the company rating was maintained by Maxim Group. The firm has “Buy” rating by Maxim Group given on Monday, July 17. The firm has “Buy” rating by Aegis Capital given on Wednesday, October 26. WBB Securities upgraded the shares of CTSO in report on Thursday, October 29 to “Buy” rating. Maxim Group maintained the stock with “Buy” rating in Wednesday, July 5 report. On Friday, October 7 the stock rating was initiated by B. Riley & Co with “Buy”. The stock has “Buy” rating by Aegis Capital on Tuesday, May 30. Maxim Group initiated Cytosorbents Corp (NASDAQ:CTSO) rating on Tuesday, May 24. Maxim Group has “Buy” rating and $8 target.

More notable recent Cytosorbents Corp (NASDAQ:CTSO) news were published by: Prnewswire.com which released: “CytoSorbents Announces Pricing of Follow-On Offering” on March 31, 2017, also Seekingalpha.com with their article: “Cytosorbents: A Razor & Razor Blade Story” published on June 28, 2017, Seekingalpha.com published: “CytoSorbents’ (CTSO) CEO Dr. Phillip Chan on Q2 2017 Results – Earnings Call …” on August 08, 2017. More interesting news about Cytosorbents Corp (NASDAQ:CTSO) were released by: Seekingalpha.com and their article: “Cytosorbents’ (CTSO) CEO Phillip Chan on Q1 2017 Results – Earnings Call …” published on May 09, 2017 as well as Seekingalpha.com‘s news article titled: “Why CytoSorbents And Spectral Medical Inc Are Not Good Stocks For A Long Position” with publication date: August 04, 2017.

CytoSorbents Corporation is a critical care focused immunotherapy company. The company has market cap of $154.74 million. The Firm is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. It currently has negative earnings. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.